Impax reaches $20 million deal to end trial over generic drug's delay

BOSTON (Reuters) - Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn.